Back to Journals » Chronic Wound Care Management and Research » Volume 1

Safety and efficacy of Becaplermin gel in the treatment of diabetic foot ulcers

Authors Blume P, Bowlby M, Schmidt B, Donegan R

Received 26 March 2014

Accepted for publication 31 May 2014

Published 29 July 2014 Volume 2014:1 Pages 11—14

DOI https://doi.org/10.2147/CWCMR.S64905

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Peter Blume,1 Melinda Bowlby,2 Brian M Schmidt,2 Ryan Donegan2

1Orthopedics and Rehabilitation, and Anesthesia, Yale School of Medicine, 2Section of Podiatric Surgery, Department of Orthopedics and Rehabilitation, Yale New Haven Hospital, New Haven, CT, USA

Abstract: Becaplermin gel remains the only US Food and Drug Administration (FDA)-approved growth factor for the treatment of diabetic neuropathic foot ulcers. Becaplermin gel has shown to be efficacious in a number of clinical trials. The FDA has added a black box warning label about the risk of cancer associated with the use of three or more Becaplermin tubes. Other adverse drug reactions associated with Becaplermin gel use are minimal. There is a need for further research regarding the true correlation between cancer and Becaplermin gel use.

Keywords: diabetic, ulcer, wound care, advanced biologic therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]